Merck's Keytruda Marches On In Melanoma With NICE Nod
This article was originally published in Scrip
Merck & Co. Inc.'s PD-1 inhibitor Keytruda (pembrolizumab) has been given the provisional green light from the British national health technology association NICE as a treatment for some patients with advanced melanoma which is either inoperable or metastatic – provided the US drug maker makes the immune-oncology therapy available at an agreed discounted price.
You may also be interested in...
A Phase III clinical trial comparing AbbVie's Skyrizi with Novartis's IL-17 agonist Cosentyx showed the former's superiority in adults with moderate-to-severe plaque psoriasis.
Acasti’s omega-3 candidate drug CaPre missed the primary endpoint in TRILOGY-1 due to an unexplained high placebo effect, as AstraZeneca said its STRENGTH study was unlikely to show a treatment benefit.
MorphoSys has chosen Incyte as its global partner for commercializing and further developing its lead asset, the Fc-engineered antibody tafasitamab that targets CD19.